![[CCO] Certification Coaching Organization LLC](https://www.cco.us/wp-content/uploads/2015/05/CCO-Logo-2015-d3-500px.png "[CCO] Certification Coaching Organization LLC"){kind=logo}
🔍 Section 1 — Definition
COVID-19 (Coronavirus Disease 2019) is an infectious illness caused by the SARS-CoV-2 virus, first identified in late 2019. The disease ranges from asymptomatic infection to critical illness with multi-organ failure. For ICD-10-CM reporting purposes, code U07.1, COVID-19, is the primary classification under Chapter 22 (Codes for Special Purposes, U00–U85), per CMS FY2026 ICD-10-CM Official Guidelines for Coding and Reporting.
Post-COVID-19 Condition (also called Long COVID or PASC — Post-Acute Sequelae of SARS-CoV-2 Infection) refers to a wide range of new, returning, or ongoing health problems that people experience four or more weeks after first being infected with SARS-CoV-2. These conditions persist after the acute phase of infection has resolved. ICD-10-CM code U09.9, Post COVID-19 condition, unspecified, was effective October 1, 2021, and remains the anchor code for post-COVID sequelae, per CDC NCHS announcement.
Multisystem Inflammatory Syndrome (MIS) — including MIS in Children (MIS-C) and MIS in Adults (MIS-A) — is a serious hyperinflammatory condition associated with SARS-CoV-2, coded to M35.81, Multisystem inflammatory syndrome. Coding conventions differ depending on whether the patient has active COVID-19, a history of COVID-19, or only exposure to COVID-19, as detailed in FY2026 Guideline I.C.1.g.1.l.
Effective April 1, 2025, a significant guideline change took effect: U07.1 should only be assigned when the provider documents a confirmed diagnosis of COVID-19. A positive test result alone, without provider documentation confirming the diagnosis, is no longer sufficient. Query the provider when asymptomatic patients test positive if no confirmation is documented, per the April 1, 2025 guideline update.
🗂️ Section 2 — Alternative Terminology
COVID-19 and its sequelae are referred to by numerous clinical, lay, and administrative terms. Coders and CDI specialists must recognize all variants to ensure correct code assignment and complete documentation capture.
| Formal / Clinical Term | Colloquial / Lay / Administrative Names |
|---|---|
| COVID-19 (Coronavirus Disease 2019) | COVID, The virus, coronavirus, novel coronavirus, SARS-CoV-2 infection |
| Post COVID-19 Condition (U09.9) | Long COVID, Long-haul COVID, Long-haul syndrome, PASC, post-COVID syndrome, post-acute COVID |
| Post-Acute Sequelae of SARS-CoV-2 (PASC) | Long COVID, COVID long-hauler symptoms, chronic COVID |
| Multisystem Inflammatory Syndrome in Children (MIS-C) | Pediatric inflammatory multisystem syndrome (PIMS), COVID-associated multisystem inflammation |
| Multisystem Inflammatory Syndrome in Adults (MIS-A) | Adult MIS, COVID hyperinflammatory syndrome |
| Pneumonia due to SARS-CoV-2 (J12.82) | COVID pneumonia, coronavirus pneumonia, SARS-CoV-2 pneumonia |
| COVID-19 with sepsis | COVID sepsis, septicemia due to COVID |
| Personal history of COVID-19 (Z86.16) | Previous COVID, prior COVID infection, resolved COVID |
| Contact/exposure to COVID-19 (Z20.822) | COVID exposure, close contact with COVID case |
| Encounter for COVID-19 screening (Z11.52) | COVID screening, pre-op COVID test, routine COVID test |
🩺 Section 3 — Signs & Symptoms
COVID-19 presents across a broad spectrum. When a definitive diagnosis of COVID-19 has not been established, coders assign the presenting signs and symptoms rather than U07.1, per FY2026 Guideline I.C.1.g.1.g.
Acute COVID-19 — Common Presenting Signs/Symptoms:
- Fever (R50.9), chills (R68.83)
- Cough — acute (R05.1), unspecified (R05.9)
- Shortness of breath / dyspnea (R06.02)
- Fatigue (R53.83)
- Myalgia (M79.3)
- Headache (R51.9)
- Loss of smell / anosmia (R43.0)
- Loss of taste / ageusia (R43.2)
- Sore throat (J02.9)
- Nausea, vomiting, diarrhea (R11.0, R11.10, R19.7)
- Chest pain (R07.9)
Post-COVID-19 (Long COVID) — Persistent/New Symptoms:
- Fatigue / post-exertional malaise (R53.83)
- Brain fog / cognitive impairment (R41.840)
- Dyspnea / breathlessness (R06.02)
- Palpitations (R00.2)
- Persistent anosmia (R43.0) or ageusia (R43.2)
- Post-exertional symptom exacerbation
- Sleep disturbance (G47.00)
- Depression (F32.9), anxiety (F41.9)
- Orthostatic intolerance / POTS (G90.3)
- Chronic respiratory failure (J96.10)
When the provider has documented a confirmed diagnosis of COVID-19 or post-COVID condition, do not separately code the presenting signs and symptoms. However, when coding long COVID (U09.9), you should code the specific manifestation first (e.g., R06.02 for dyspnea, J84.10 for pulmonary fibrosis), followed by U09.9, per the “code first” instruction at U09.9 in the ICD-10-CM tabular.
🧭 Section 4 — Differential Diagnosis
COVID-19 shares symptoms with a wide range of respiratory and systemic illnesses. Clinical differentiation relies on testing, clinical context, and provider documentation. Coders should not independently determine whether a patient has COVID-19 vs. an alternative diagnosis.
| Differential Diagnosis | Key Distinguishing Features | ICD-10-CM Code |
|---|---|---|
| Influenza | Seasonal pattern, influenza testing positive, abrupt onset | J09.X1–J11.1 |
| Bacterial pneumonia | Lobar consolidation, purulent sputum, elevated WBC, culture positive | J13–J18.9 |
| RSV infection | Common in children/elderly, RSV testing positive | J21.0, J06.9 |
| Sepsis (non-COVID) | Identified bacterial/fungal source, negative COVID testing | A41.9, A40.xx |
| ARDS (non-COVID) | Other underlying cause documented, no COVID confirmed | J80 |
| Pulmonary embolism | D-dimer elevated, CT pulmonary angiography positive | I26.09, I26.99 |
| Myocarditis / pericarditis | Cardiac biomarkers, echo findings, non-COVID pathogen | I40.9, I30.9 |
| Chronic fatigue syndrome | Not linked to COVID-19 infection, prior ME/CFS diagnosis | G93.32 |
| Anxiety / depression (primary) | No post-COVID link documented; psychiatric etiology | F41.9, F32.9 |
| Kawasaki disease | Children, classic Kawasaki features, no COVID exposure/history | M30.3 |
Do not assign U09.9 (post-COVID) for conditions that may be related to COVID-19 unless the provider explicitly documents the causal link. A temporal relationship alone (i.e., symptoms occurred after COVID-19 infection) is insufficient — the provider must document that the condition is a sequela of, or related to, a previous COVID-19 infection.
📋 Section 5 — Clinical Indicators for Coders/CDI
The following clinical indicators help coders and CDI specialists identify opportunities to accurately report COVID-19 and post-COVID conditions. Documentation must support each code assigned.
| Clinical Indicator | Code Consideration | Action |
|---|---|---|
| Positive COVID-19 PCR or antigen test + provider confirmation | U07.1 | Assign U07.1 as PDx if active infection drives encounter |
| Provider documents “COVID-19” without positive test | U07.1 | Provider documentation alone is sufficient for confirmation (April 2025 guideline) |
| Documented “suspected,” “probable,” or “possible” COVID-19 | Sign/symptom codes only | Do NOT assign U07.1; code presenting signs/symptoms |
| Provider documents COVID-19 pneumonia or “pneumonia due to COVID-19” | U07.1 + J12.82 | Assign both; U07.1 first, J12.82 as additional diagnosis |
| COVID-19 progresses to sepsis | U07.1 + A41.89 + R65.20/21 | Follow sepsis sequencing rules (Section I.C.1.d) |
| Acute COVID-19 with ARDS | U07.1 + J80 | U07.1 first; J80 as additional |
| Post-COVID fatigue documented by provider | R53.83 + U09.9 | Specific condition code first, then U09.9 |
| Post-COVID brain fog / cognitive dysfunction | R41.840 + U09.9 | Specific condition code first, then U09.9 |
| Post-COVID pulmonary fibrosis | J84.10 + U09.9 | Specific condition code first, then U09.9 |
| MIS with active COVID-19 | U07.1 + M35.81 | U07.1 first; M35.81 additional; add codes for complications |
| MIS following previous COVID-19 (history) | M35.81 + U09.9 | M35.81 first; U09.9 additional per FY2026 guidelines |
| Resolved COVID-19 / follow-up without residuals | Z09 + Z86.16 | Z09 principal; Z86.16 additional |
| Personal history of COVID-19 (no current infection/sequelae) | Z86.16 | Additional code when relevant; not PDx for unrelated encounters |
| COVID-19 during pregnancy | O98.5x + U07.1 + manifestation codes | Chapter 15 codes always take sequencing priority |
| Newborn positive for COVID-19 | U07.1 (+ Z38.xx as PDx for birth episode) | Z38.xx as PDx for birth; U07.1 + manifestations as additional |
When the medical record documents COVID-19 with significant respiratory compromise requiring ICU-level care, O2 supplementation, or ventilator support, consider querying the provider to clarify whether the patient’s condition meets the criteria for sepsis or acute respiratory failure. These distinctions significantly affect MS-DRG assignment and reimbursement (e.g., DRG 177 vs. DRG 870/871 for sepsis).
🦴 Section 6 — Anatomy & Pathophysiology
SARS-CoV-2 is a positive-sense, single-stranded RNA betacoronavirus. It enters human cells primarily via the ACE2 receptor (angiotensin-converting enzyme 2), expressed abundantly in type II pneumocytes, endothelial cells, intestinal epithelium, and cardiac tissue. The spike (S) protein binds ACE2 with assistance from the host serine protease TMPRSS2.
Acute Phase Pathophysiology:
- Pulmonary involvement: Viral replication causes diffuse alveolar damage (DAD), with exudative and proliferative phases. Cytokine storm — marked by elevated IL-6, TNF-α, IL-1β — drives ARDS, endotheliitis, and microvascular thrombosis.
- Cardiovascular: Direct myocardial injury (myocarditis), arrhythmias, and thromboembolic events (PE, DVT) due to hypercoagulability (elevated D-dimer, fibrinogen).
- Neurological: Neuroinvasion via olfactory neurons explains anosmia; encephalopathy may result from hypoxia, cytokine-mediated neuroinflammation, or direct viral invasion.
- Renal: Acute kidney injury (AKI) occurs due to direct tubular injury, hemodynamic compromise, and microvascular thrombosis.
Post-COVID Pathophysiology (PASC):
Research suggests multiple overlapping mechanisms for long COVID, including: (1) viral persistence or reactivation; (2) immune dysregulation with autoantibody formation; (3) microbiome disruption; (4) endothelial dysfunction and microclotting; and (5) reactivation of latent herpesviruses (e.g., EBV). These mechanisms explain the diverse manifestations from fatigue and brain fog to dysautonomia (POTS), mast cell activation, and cardiopulmonary symptoms.
MIS-C / MIS-A Pathophysiology:
MIS is a post-infectious hyperinflammatory syndrome distinct from acute COVID-19. It is hypothesized to involve immune complex deposition, molecular mimicry, and aberrant T-cell activation. MIS-C typically presents 2–6 weeks after acute infection, predominantly in children, with fever, gastrointestinal symptoms, mucocutaneous changes, and cardiac involvement (coronary artery dilation, myocarditis).
💊 Section 7 — Medication Impact / Treatment
Several antiviral and immunomodulatory agents are used in COVID-19 treatment; their use in the medical record should alert coders and CDI specialists to the confirmed or suspected diagnosis.
Antiviral Agents:
- Nirmatrelvir/ritonavir (Paxlovid): FDA-approved oral antiviral for mild-to-moderate COVID-19 in high-risk adults (≥18 years); EUA for adolescents 12–17 years weighing ≥40 kg. Use of Paxlovid in the record strongly indicates a confirmed COVID-19 diagnosis (U07.1). Per 2026 clinical policy guidance, eligible claims must include ICD-10-CM diagnosis code U07.1.
- Remdesivir (Veklury): IV antiviral for hospitalized patients; administered per hospital protocol. Strong indicator of confirmed acute COVID-19.
- Molnupiravir (Lagevrio): Oral antiviral for high-risk adults; not authorized for pediatric patients under 18.
Immunomodulatory / Anti-inflammatory Agents:
- Dexamethasone: Standard of care for hospitalized patients requiring supplemental oxygen or ventilation (RECOVERY trial). Documents disease severity. Presence of corticosteroid therapy should prompt CDI review for severity of illness documentation.
- Baricitinib (Olumiant): JAK inhibitor approved for severe COVID-19 in hospitalized adults.
- Tocilizumab (Actemra): IL-6 receptor antagonist for hospitalized patients with rapid respiratory deterioration; HCPCS code Q0234 (tocilizumab-bavi) effective July 2026 per CMS Transmittal R13733CP.
Vaccination — Coding:
COVID-19 vaccination status should be documented. Vaccine administration is reported with CPT codes 90476–91300 series. Combined COVID-19/influenza mRNA vaccines include CPT 90612 and 90613 (new for CY2026), per AMA CPT COVID-19 vaccine codes.
The presence of remdesivir, dexamethasone, baricitinib, or tocilizumab in a hospitalized patient’s medication administration record should be documented by the provider as specific treatment for COVID-19. Without provider documentation explicitly linking these treatments to a confirmed COVID-19 diagnosis, the coder cannot assign U07.1 based on medication use alone. Ensure the physician’s assessment clearly states “COVID-19” is the reason for these therapies.
Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.
← Back to All Clinical Documentation Guides
📘 Section 8 — ICD-10-CM Guidelines (FY2026)
The following guidelines govern COVID-19 coding for fiscal year 2026 (October 1, 2025 – September 30, 2026). All coders and CDI specialists should reference CMS FY2026 ICD-10-CM Official Guidelines Section I.C.1.g as the primary authority.
Guideline I.C.1.g.1 — COVID-19 Infection
(a) Code Only Confirmed Cases: Assign U07.1 only when the provider documents a confirmed diagnosis of COVID-19. As of April 1, 2025, confirmation by positive test result alone (without provider documentation) is no longer sufficient. For asymptomatic patients with a positive test but no provider confirmation, query the provider. “Suspected,” “possible,” “probable,” or “inconclusive” COVID-19 → code signs and symptoms only.
(b) Sequencing of Codes: When COVID-19 is the principal/first-listed diagnosis, sequence U07.1 first, followed by associated manifestations. Exceptions: obstetric cases (Chapter 15 sequencing takes priority), sepsis, transplant complications.
(c) Acute Respiratory Manifestations:
- Pneumonia due to COVID-19: U07.1 + J12.82
- Acute bronchitis due to COVID-19: U07.1 + J20.8
- Bronchitis NOS due to COVID-19: U07.1 + J40
- ARDS due to COVID-19: U07.1 + J80
- Acute respiratory failure due to COVID-19: U07.1 + J96.0-
- Lower respiratory infection NOS: U07.1 + J22
(d) Non-Respiratory Manifestations: When the reason for encounter is a non-respiratory manifestation (e.g., viral enteritis, cardiac involvement), assign U07.1 first and the manifestation code(s) as additional diagnoses.
(e) Exposure to COVID-19 (Z20.822): For asymptomatic individuals with actual or suspected exposure, assign Z20.822. For symptomatic individuals where infection has been ruled out or results are inconclusive, also assign Z20.822. As refined post-pandemic, Z20.822 requires explicit documentation of contact with a confirmed case. Do not assign Z20.822 for every patient tested — if no exposure is documented, use Z11.52 for screening, per Solventum 2026 coding guidance.
(f) Screening (Z11.52): Assign Z11.52 for encounters where COVID-19 screening is performed without known exposure, symptoms, or infection — including routine pre-operative testing.
(g) Signs and Symptoms Without Definitive Diagnosis: When no COVID-19 diagnosis is confirmed, code specific signs: R05.1 (acute cough), R05.9 (cough unspecified), R06.02 (shortness of breath), R50.9 (fever, unspecified).
(h) Asymptomatic Positive Tests: Query the provider; do not automatically assign U07.1 if provider has not confirmed diagnosis.
(i) Personal History of COVID-19 (Z86.16): Assign for patients with a resolved, prior COVID-19 infection without current sequelae.
(j) Follow-Up Visits After COVID-19 Resolution: Without residual symptoms: Z09 + Z86.16. With ongoing symptoms related to prior COVID-19: follow guideline I.C.1.g.1.m (post-COVID).
(l) Multisystem Inflammatory Syndrome (MIS):
- Active COVID-19 with MIS: U07.1 + M35.81
- History of COVID-19, now MIS: M35.81 + U09.9
- Only COVID-19 exposure (no infection/history), now MIS: M35.81 + Z20.822
(m) Post COVID-19 Condition (U09.9): For sequelae or associated symptoms following a previous COVID-19 infection, assign the specific condition code first, then U09.9. U09.9 is not used for active COVID-19 manifestations. U09.9 may be used together with U07.1 when a patient with post-COVID conditions develops a new, active COVID-19 infection.
(n) Underimmunization Status: Z28.310 (unvaccinated) or Z28.311 (partially vaccinated) may be assigned as additional information.
Special Populations:
- Pregnancy: O98.5- sequenced first, then U07.1 + manifestations
- Newborns: U07.1 as additional; Z38.xx as PDx for birth episode; P35.8 + U07.1 if contracted in utero
Active vs. History vs. Post-COVID Summary:
• Active COVID-19 → U07.1 (+ manifestation codes)
• Resolved COVID-19, no residuals → Z86.16 (+ Z09 for follow-up)
• Post-COVID sequelae → Specific condition code + U09.9
• Prior COVID-19 + new active COVID → U07.1 + U09.9 + specific condition codes for both
• MIS post-COVID → M35.81 + U09.9
🔢 Section 9 — ICD-10-CM Code Set (FY2026)
The following codes are active for FY2026 (effective October 1, 2025). All codes verified against the CMS FY2026 ICD-10-CM tabular and CDC NCHS ICD-10-CM code files.
| ICD-10-CM Code | Description | Notes / Sequencing |
|---|---|---|
| U07.1 | COVID-19 | PDx when active infection is reason for encounter; confirmed diagnosis only (effective April 2025) |
| J12.82 | Pneumonia due to coronavirus disease 2019 | Always secondary to U07.1; “Code first” U07.1 |
| U09.9 | Post COVID-19 condition, unspecified (PASC / Long COVID) | Never used for active COVID; always secondary to specific condition code |
| M35.81 | Multisystem inflammatory syndrome (MIS-C / MIS-A) | Sequencing depends on active COVID vs. post-COVID vs. exposure — see Sec. 8 |
| Z86.16 | Personal history of COVID-19 | Resolved COVID without current sequelae; additional code in relevant contexts |
| Z20.822 | Contact with and (suspected) exposure to COVID-19 | Requires explicit documented exposure to confirmed case; post-pandemic narrowing |
| Z11.52 | Encounter for screening for COVID-19 | Asymptomatic, no known exposure; pre-op testing, routine facility protocol |
| Z28.310 | Unvaccinated for COVID-19 | Additional code when clinically relevant |
| Z28.311 | Partially vaccinated for COVID-19 | Additional code when clinically relevant |
| J80 | Acute respiratory distress syndrome (ARDS) | Additional code when ARDS complicates COVID-19 (secondary to U07.1) |
| J96.00 | Acute respiratory failure, unspecified whether with hypoxia or hypercapnia | Additional code with U07.1 when acute respiratory failure present |
| J96.01 | Acute respiratory failure with hypoxia | Additional code; specify if hypoxia documented |
| J96.10 | Chronic respiratory failure, unspecified | May appear as post-COVID sequela; code first, then U09.9 |
| J84.10 | Pulmonary fibrosis, unspecified | Post-COVID pulmonary fibrosis; code first, then U09.9 |
| A41.89 | Other specified sepsis | COVID-19 sepsis — assign with U07.1 and sepsis sequencing rules |
| R65.20 | Severe sepsis without septic shock | With COVID-19 sepsis when criteria met |
| R65.21 | Severe sepsis with septic shock | With COVID-19 sepsis and shock |
| R53.83 | Other fatigue | Post-COVID fatigue; code first, then U09.9 |
| R41.840 | Attention and concentration deficit (brain fog) | Post-COVID cognitive impairment; code first, then U09.9 |
| R43.0 | Anosmia | Post-COVID anosmia; code first, then U09.9 |
| R43.2 | Parageusia (taste disturbance) | Post-COVID taste disturbance; code first, then U09.9 |
| G90.3 | Multi-system degeneration of the autonomic nervous system (POTS/dysautonomia) | Post-COVID dysautonomia; code first, then U09.9 |
| I26.09 | Other pulmonary embolism without acute cor pulmonale | PE as COVID complication; code first, then U07.1 or U09.9 |
| O98.511 | Other viral diseases complicating pregnancy, first trimester | COVID in pregnancy; always sequence O98.5- first |
| Z09 | Encounter for follow-up examination after completed treatment for conditions other than malignant neoplasm | Follow-up after resolved COVID-19; pair with Z86.16 |
Avoid assigning J12.89 (Other viral pneumonia) for COVID-19 pneumonia. Since FY2021, the specific code J12.82 (Pneumonia due to coronavirus disease 2019) replaced J12.89 for SARS-CoV-2 pneumonia. Using J12.89 for a confirmed COVID-19 pneumonia case is a documentation and coding error that affects MS-DRG assignment and data integrity. Verify that your encoder has been updated to J12.82.
🔎 Section 10 — Indexing
The following ICD-10-CM Alphabetic Index entries guide coders to correct COVID-19 and post-COVID codes. Always verify in the Tabular List after indexing to confirm instructional notes and correct code selection.
| Index Entry (Main Term → Subterm) | ICD-10-CM Code |
|---|---|
| COVID-19 | U07.1 |
| Coronavirus — see also COVID-19 | U07.1 |
| SARS-CoV-2 — see COVID-19 | U07.1 |
| Pneumonia → coronavirus disease 2019 (COVID-19) | J12.82 |
| Pneumonia → SARS-CoV-2 | J12.82 |
| Post-COVID → condition (unspecified) | U09.9 |
| Long COVID — see Post-COVID, condition | U09.9 |
| Syndrome → post-acute sequelae of COVID-19 (PASC) | U09.9 |
| Multisystem inflammatory syndrome (MIS) | M35.81 |
| History (personal) → COVID-19 | Z86.16 |
| Contact (with) → COVID-19 | Z20.822 |
| Exposure to → COVID-19 | Z20.822 |
| Screening → COVID-19 (encounter for) | Z11.52 |
| Vaccination status → not done → COVID-19 | Z28.310 |
| Vaccination status → partial → COVID-19 | Z28.311 |
The term “Long COVID” does not appear as a standalone main term in the Alphabetic Index in all encoder editions. Search under “Post-COVID” or “Post-acute sequelae” if your encoder does not recognize “Long COVID” directly. Always confirm with the Tabular List to review the “code first” instruction at U09.9, which requires the specific manifestation code to be sequenced first.
🏥 Section 11 — CPT (2026)
The following CPT codes apply to evaluation, testing, treatment, and management of COVID-19 in CY2026. All codes verified against AMA CPT COVID-19 codes and CMS CY2026 CPT/HCPCS code list.
| CPT Code | Description | Global / Setting | Notes |
|---|---|---|---|
| 87635 | Infectious agent detection by nucleic acid (DNA or RNA); SARS-CoV-2 (COVID-19), amplified probe technique (PCR) | Lab / No global | Definitive molecular test; most specific for COVID-19 PCR diagnosis; bill per AMA guidance |
| 87426 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) antigen, qualitative or semiquantitative | Lab / POC / No global | Rapid antigen test; point-of-care; per AAPC 87426 |
| 87811 | Infectious agent antigen detection by immunoassay with direct optical observation; SARS-CoV-2 | Lab / POC / No global | Rapid antigen detection with visual read; home test reporting |
| 86413 | SARS-CoV-2 (COVID-19) antibody; quantitative | Lab / No global | Antibody testing; use Z01.84 for non-diagnostic antibody response examination |
| 99213–99215 | Office/Outpatient E/M, established patient (levels 3–5) | Office / No global | Post-COVID management visits; level based on MDM or total time |
| 99221–99223 | Initial hospital inpatient/observation E/M | Hospital / No global | Initial care for hospitalized COVID-19 patients |
| 99291–99292 | Critical care, per 30 min (first 30–74 min / additional) | Hospital / No global | Severe COVID-19 with ARDS, sepsis, ventilator support |
| 94002–94004 | Ventilation assist and management | Hospital / No global | Mechanical ventilation management for severe COVID-19 ARDS |
| 91300 | SARS-CoV-2 mRNA vaccine, monovalent, for IM use (consolidated vaccine product code) | Preventive / No global | mRNA COVID-19 vaccine (Moderna/Pfizer updated formulas) |
| 91304 | SARS-CoV-2 recombinant spike protein nanoparticle vaccine (Novavax); 5 mcg/0.5 mL, IM | Preventive / No global | Protein subunit vaccine; per AMA vaccine code update |
| 90612 | Influenza + SARS-CoV-2 combination vaccine, trivalent flu, mRNA-LNP, 31.7 mcg/0.32 mL, IM | Preventive / No global | New CY2026 combination flu+COVID vaccine; per CPT 2026 updates |
| 90613 | Influenza + SARS-CoV-2 combination vaccine, quadrivalent flu, mRNA-LNP, 40 mcg/0.4 mL, IM | Preventive / No global | New CY2026 combination flu+COVID vaccine |
| 0001A–0004A | Immunization administration for SARS-CoV-2 vaccine (per dose, per injection) | Office / No global | Administration codes paired with vaccine product codes |
🧾 Section 12 — HCPCS (2026)
The following HCPCS Level II codes apply to COVID-19 testing, treatment, and related services in CY2026, per CMS Annual Update to the List of CPT/HCPCS Codes (January 1, 2026) and CMS Transmittal R13733CP.
| HCPCS Code | Description | Typical Use |
|---|---|---|
| U0001 | CDC 2019 novel Coronavirus (2019-nCoV) real-time RT-PCR diagnostic panel | CDC-authorized lab testing; Medicare reimbursement for PCR |
| U0002 | 2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (non-CDC) | Non-CDC lab testing; broad technique designation; reimbursed at ~$51 |
| U0003 | SARS-CoV-2 (COVID-19) testing, high-throughput technologies, non-CDC | High-throughput facility testing |
| U0004 | SARS-CoV-2 (COVID-19) testing, high-throughput technologies, non-CDC, including result reporting | High-throughput testing with reporting component |
| U0005 | Infectious agent detection by nucleic acid (DNA or RNA); SARS-CoV-2 (COVID-19), high throughput, ≤2 hours | Rapid high-throughput molecular testing (≤2 hours) |
| M0220 | Administration of COVID-19 antiviral (nirmatrelvir/ritonavir — Paxlovid) in patient’s home | Home Paxlovid administration |
| M0221 | Administration of COVID-19 antiviral (nirmatrelvir/ritonavir — Paxlovid) in healthcare setting | Clinic/hospital Paxlovid administration |
| Q0234 | Injection, tocilizumab-bavi, for hospitalized adult patients with COVID-19 (effective July 1, 2026) | New HCPCS effective July 2026; per CMS R13733CP |
| Q0235 | Injection, COVID-19 monoclonal antibody product, not otherwise classified (NOC) | NOC code for monoclonal antibody products not yet assigned specific HCPCS |
| M0231 | Administration code for COVID-19 monoclonal antibody (paired with Q0234) | Administration in healthcare setting (Q0234 product) |
| M0232 | Administration code for COVID-19 monoclonal antibody, additional charge | Additional administration component (Q0234 product) |
COVID-19 vaccines remain on the CY2026 Code List as designated health services and are eligible for the preventive services exception at § 411.355(h) for Medicare. Providers billing for COVID-19 vaccine administration to Medicare patients should use the CPT product code + administration code (0001A–0004A series). Confirm modifier usage with your MAC, as requirements may vary post-PHE.
📚 Section 13 — AHA Coding Clinic (Recent Guidance)
The AHA Coding Clinic provides authoritative guidance on ICD-10-CM/PCS coding questions. Key COVID-19 Coding Clinic guidance includes:
| Coding Clinic Reference / Topic | Guidance Summary | Code Impact |
|---|---|---|
| AHA COVID-19 FAQ (updated through 2022) — Post-COVID Pulmonary Embolism | For PE as a sequela of previous COVID-19 (patient no longer has active COVID-19), assign PE code as PDx + U09.9 as secondary | I26.99 + U09.9 |
| AHA FAQ — COVID-19 Pneumonia Specificity | Use J12.82 (not J12.89) for pneumonia confirmed due to COVID-19 effective FY2021+ | U07.1 + J12.82 (not J12.89) |
| AHA FAQ — MIS Sequencing | MIS with active COVID: U07.1 as PDx + M35.81. MIS following resolved COVID: M35.81 + B94.8 (pre-Oct 2021) or M35.81 + U09.9 (Oct 2021 onward) | M35.81 + U09.9 (current) |
| AHA FAQ — Post-COVID Weakness / Anorexia | Post-COVID syndrome with generalized weakness and lack of appetite: R53.1 + R63.0 + U09.9 | R53.1 + R63.0 + U09.9 |
| AHA FAQ — Chronic Respiratory Failure Post-COVID | Assign chronic respiratory failure code as PDx + U09.9 as secondary when ARDS has resolved but chronic respiratory failure persists | J96.10 + U09.9 |
| AHA FAQ — Guillain-Barré Syndrome Post-COVID | Guillain-Barré as sequela of COVID-19: G61.0 + U09.9 | G61.0 + U09.9 |
| AHA FAQ — Positive Test After Vaccination | If provider documents COVID-19 despite vaccination + positive test, assign U07.1; vaccination does not preclude COVID-19 infection coding | U07.1 |
| AHA FAQ — Debility from Prolonged Hospitalization | Do NOT assign U09.9 for debility due to prolonged hospitalization (deconditioning from hospitalization, not COVID sequelae) | U09.9 NOT appropriate; use debility code alone |
| AAPC — Long COVID Coding (Dec 2024) | Long COVID = post-COVID condition; follow Guideline I.C.1.g.1.m; code specific manifestation first, then U09.9; clinical evaluation needed before definitive diagnosis | Manifestation code + U09.9 |
A common audit finding involves assigning U09.9 (post-COVID) without provider documentation explicitly linking the current condition to a previous COVID-19 infection. Auditors look for provider documentation that states the condition is “due to,” “related to,” “a sequela of,” or “as a result of” prior COVID-19. Temporal correlation alone (symptoms started after COVID-19 recovery) is insufficient. Ensure provider attestation exists in the record before assigning U09.9.
💰 Section 14 — HCC / Risk Adjustment (v28)
CMS-HCC Model V28 is fully operative as of payment year 2026 (100% V28), replacing V24 entirely. V28 expanded HCC categories from 86 to 115 while reducing valid ICD-10-CM codes from 9,797 to 7,770, per RAAPID V28 analysis. COVID-19 and post-COVID codes have specific V28 implications for Medicare Advantage risk adjustment.
| ICD-10-CM Code | HCC v28 Category | HCC Name | Relative Factor (Community, NonDual, Aged) | RAF Impact Notes |
|---|---|---|---|---|
| U07.1 (with sepsis: A41.89 + R65.20/21) | HCC 2 | Septicemia, Sepsis, SIRS/Shock | ~0.447 (proposed +15.6% in 2027 advance notice) | COVID-19 coding to HCC 2 only when sepsis criteria documented; high-value RAF per V28 analysis |
| J12.82 (Pneumonia due to COVID-19) | HCC 280 | COPD, Interstitial Lung Disorders, and Other Chronic Lung Disorders | ~0.319 | J12.82 maps to HCC 280 in v28 as a specified pneumonia type; per HCC 280 V28 mapping |
| J80 (ARDS) | HCC 84 | Respiratory Arrest and Failure; Acute Pulmonary Edema | Varies by severity | ARDS from COVID maps to HCC 84 when documented; MCC-level complication affecting DRG |
| J84.10 (Pulmonary fibrosis — post-COVID) | HCC 280 | COPD, Interstitial Lung Disorders, and Other Chronic Lung Disorders | ~0.319 | Post-COVID pulmonary fibrosis generates HCC 280 RAF when documented as a current, active condition with MEAT criteria |
| U09.9 alone | No HCC mapping | — | 0 | U09.9 itself does not map to a V28 HCC; RAF value comes from the specific condition codes coded first (e.g., J84.10, G61.0, J96.10) |
| M35.81 (MIS) | Varies by complication | — | Depends on documented complications | MIS itself does not have a standalone V28 HCC; RAF generated through associated conditions (cardiac, renal, sepsis) |
| Z86.16 (History of COVID-19) | No HCC mapping | — | 0 | History codes do not generate HCC RAF; only current/active conditions with MEAT documentation qualify |
| I26.09/I26.99 (PE — post-COVID) | HCC 107 | Vascular Disease with Complications | Varies | PE as post-COVID sequela (U09.9) generates HCC 107 if current and documented; requires MEAT criteria |
For Medicare Advantage patients with a post-COVID condition generating an HCC (e.g., pulmonary fibrosis J84.10, chronic respiratory failure J96.10, autonomic neuropathy), ensure the provider’s documentation includes MEAT criteria — Management (active treatment), Evaluation (diagnostic workup), Assessment (clinical judgment), or Treatment (therapeutic intervention) — linked to a current face-to-face encounter. V28 has no tolerance for historical diagnoses carried forward without current visit documentation. Query if documentation only references “history of” without current management.
✍️ Section 15 — CDI Query Templates
All query templates below comply with ACDIS and AHIMA standards: non-leading, clinically supported, multiple-choice format with an option for “clinically undetermined.”
| Query Scenario | Query Wording (Non-Leading, Multiple-Choice) |
|---|---|
| Confirmed vs. Suspected COVID-19 Record documents positive COVID-19 test; provider has not explicitly stated diagnosis | The medical record documents a positive SARS-CoV-2 test result. Based on your clinical assessment, does this patient have: □ Confirmed COVID-19 (U07.1) □ Suspected COVID-19 (code signs/symptoms only) □ Other: _______________ □ Clinically undetermined |
| COVID-19 with Sepsis Hospitalized COVID-19 patient with hypotension, vasopressors, elevated lactate, organ dysfunction | The medical record for this patient with confirmed COVID-19 documents [hypotension / elevated WBC / vasopressor use / organ dysfunction]. Based on your clinical assessment, does this patient have: □ COVID-19 without sepsis □ Sepsis due to COVID-19 (without severe sepsis) □ Severe sepsis due to COVID-19 (without septic shock) □ Septic shock due to COVID-19 □ Clinically undetermined |
| Post-COVID Condition Attribution Patient with prior COVID-19 now presenting with fatigue, dyspnea, cognitive difficulties 8 weeks post-infection | This patient has a history of confirmed COVID-19 (resolved [date]) and currently presents with [fatigue / dyspnea / cognitive impairment]. Based on your clinical assessment, are the current symptoms: □ Related to / a sequela of the prior COVID-19 infection (post-COVID condition) □ A new, unrelated condition not attributed to prior COVID-19 □ Exacerbation of a pre-existing condition unrelated to COVID-19 □ Clinically undetermined |
| MIS-C / MIS-A Specification Pediatric/adult patient with fever, rash, gastrointestinal symptoms, cardiac involvement following COVID-19 exposure or infection | The medical record documents fever, [rash / conjunctivitis / GI symptoms / cardiac findings] in a patient with [known COVID-19 / history of COVID-19 / suspected COVID-19 exposure]. Based on your clinical assessment, does this patient have: □ Multisystem Inflammatory Syndrome (MIS) with active COVID-19 (U07.1 + M35.81) □ MIS following resolved COVID-19 infection (M35.81 + U09.9) □ MIS with COVID-19 exposure but no confirmed infection (M35.81 + Z20.822) □ Kawasaki disease □ Other inflammatory condition: _______________ □ Clinically undetermined |
| Active COVID vs. Resolved with Post-COVID Conditions Patient readmitted weeks after COVID-19 discharge with new respiratory symptoms | This patient was discharged on [date] following confirmed COVID-19 and now presents with [dyspnea / hypoxia / chest pain]. Based on your clinical assessment, is this: □ New active COVID-19 infection (reinfection, U07.1) □ Post-COVID-19 condition / sequela of prior infection (specific condition + U09.9) □ Exacerbation of a pre-existing pulmonary condition unrelated to COVID-19 □ Clinically undetermined |
When a hospitalized COVID-19 patient receives dexamethasone, remdesivir, baricitinib, or tocilizumab, and no explicit severity level is documented, consider querying the provider to clarify whether the patient has: (a) mild/moderate COVID-19, (b) severe COVID-19 with need for supplemental oxygen, (c) critical COVID-19 with mechanical ventilation. Severity documentation directly affects MS-DRG assignment, LOS-adjusted payment, and HCC risk capture.
🧑⚕️ Section 16 — Treatments (Clinical)
The following treatments are standard of care for COVID-19 and post-COVID conditions as of 2026. This section is provided for clinical context to support CDI documentation capture — not as clinical prescribing guidance.
Acute COVID-19 — Outpatient (Mild to Moderate, High-Risk):
- Nirmatrelvir/ritonavir (Paxlovid): 5-day oral course; initiate within 5 days of symptom onset; reduces hospitalization/death by ~89% in high-risk patients; preferred agent per NIH COVID-19 Treatment Guidelines
- Remdesivir (Veklury): 3-day IV course in outpatient setting for high-risk patients unable to take oral antivirals
- Molnupiravir (Lagevrio): Alternative oral antiviral; use only when other options are unavailable or not appropriate
Acute COVID-19 — Inpatient (Severe to Critical):
- Remdesivir: 5-day IV course for hospitalized patients requiring supplemental oxygen but not IMV
- Dexamethasone 6 mg/day × 10 days: Standard of care for patients on supplemental oxygen, HFNC, NIV, or mechanical ventilation (RECOVERY trial); reduces mortality in severe COVID-19
- Baricitinib (Olumiant): JAK inhibitor; FDA-approved addition in hospitalized patients requiring supplemental oxygen, HFNC, or IMV
- Tocilizumab (Actemra): IL-6 receptor antagonist for rapidly worsening hypoxia with elevated inflammatory markers; HCPCS Q0234 effective July 2026
- Anticoagulation: Prophylactic or therapeutic anticoagulation for COVID-19–associated coagulopathy/VTE; document indication, type, and INR/anti-Xa goals
- High-flow nasal cannula (HFNC) / Non-invasive ventilation: Bridge to mechanical ventilation; document FiO2 and flow rate
- Mechanical ventilation: Reserved for refractory respiratory failure; document IMV vs. NIV, mode, duration; critical for ICD-10-PCS procedure coding and DRG assignment
- Prone positioning: For moderate-to-severe ARDS; document as clinical intervention
Post-COVID Conditions — Management:
- Pulmonary rehabilitation: For post-COVID dyspnea and exercise intolerance; document persistence and functional limitation
- Cognitive rehabilitation / neuropsychology referral: For post-COVID brain fog (R41.840); document cognitive testing results and functional impact
- Autonomic rehabilitation / salt/fluid loading: For POTS/dysautonomia (G90.3); document tilt-table testing, HR response, and symptom duration
- Antidepressants / anxiolytics: For post-COVID depression/anxiety; document provider attribution to post-COVID condition for U09.9 coding
- Cardiology follow-up: For myocarditis, pericarditis, palpitations; document current management and evaluation findings
🎓 Section 17 — Patient Education / Summary
This section provides a plain-language summary for clinical staff and patient education support, and an audit-ready compliance checklist for coders and CDI professionals.
Patient-Facing Summary
COVID-19 is caused by the SARS-CoV-2 virus. Most people recover within 2–4 weeks. However, some people experience symptoms that last weeks, months, or longer after the initial infection — this is called Long COVID or post-COVID condition. Common long COVID symptoms include:
- Extreme tiredness (fatigue) that doesn’t improve with rest
- Difficulty thinking or concentrating (“brain fog”)
- Shortness of breath
- Loss of smell or taste
- Heart palpitations
- Dizziness when standing up
If you are experiencing these symptoms after recovering from COVID-19, tell your healthcare provider. Accurate documentation helps ensure you receive the right care and that your health records properly reflect your condition.
COVID-19 vaccines are safe and effective at reducing the risk of severe illness, hospitalization, and death. Updated vaccine formulations are available annually. Discuss your vaccination options with your provider.
Coding & CDI Compliance Checklist
| # | Compliance Check Item | Code/Guideline Reference |
|---|---|---|
| 1 | U07.1 assigned ONLY when provider has confirmed COVID-19 diagnosis (not just positive test alone, effective April 2025) | FY2026 Guideline I.C.1.g.1.a |
| 2 | “Suspected” / “possible” COVID-19 → signs/symptoms coded only (NOT U07.1) | I.C.1.g.1.a |
| 3 | U07.1 sequenced FIRST when active COVID-19 is principal diagnosis (except obstetrics, sepsis, transplant) | I.C.1.g.1.b |
| 4 | J12.82 (not J12.89) used for COVID-19 pneumonia; always secondary to U07.1 | I.C.1.g.1.c.i; AHA FAQ |
| 5 | Z20.822 assigned only when exposure to CONFIRMED case is explicitly documented (not for routine screening) | I.C.1.g.1.e; Solventum 2026 |
| 6 | Z11.52 used for asymptomatic routine screening (pre-op, facility protocol) without known exposure | I.C.1.g.1.f |
| 7 | U09.9 NOT assigned for active COVID-19 manifestations; only post-resolution sequelae with provider-documented causal link | I.C.1.g.1.m |
| 8 | Post-COVID conditions: specific condition code FIRST, then U09.9 as secondary | I.C.1.g.1.m; U09.9 tabular note |
| 9 | MIS with active COVID → U07.1 + M35.81; MIS post-COVID → M35.81 + U09.9; MIS with exposure only → M35.81 + Z20.822 | I.C.1.g.1.l |
| 10 | Sepsis sequencing rules followed when COVID-19 leads to sepsis (not defaulting to U07.1 alone) | I.C.1.d; I.C.1.g.1.b |
| 11 | Obstetric COVID: O98.5- sequenced first (Chapter 15 priority) | I.C.1.g.1 / I.C.15.s |
| 12 | Post-COVID HCC documentation meets MEAT criteria for Medicare Advantage risk capture (V28 fully in effect PY2026) | CMS HCC V28; RAAPID |
| 13 | U09.9 NOT used for debility from prolonged hospitalization (as opposed to true COVID sequelae) | AHA FAQ |
| 14 | Z86.16 and Z09 assigned for follow-up after resolved COVID without residual conditions | I.C.1.g.1.j |
| 15 | ICD-10-PCS procedure codes (mechanical ventilation, ECMO, prone positioning) captured for inpatient cases | ICD-10-PCS guidelines; DRG impact |
Key Sources & References
- CMS FY2026 ICD-10-CM Official Guidelines for Coding and Reporting
- CDC NCHS ICD-10-CM FY2026 Code Files
- AHA Coding Clinic — COVID-19 FAQ
- Solventum — Post-Pandemic ICD-10 Coding: Z11.52, Z20.822, U07.1 (Feb 2026)
- RAAPID — CMS-HCC Model V28: Full List of Chronic Conditions (2026)
- AMA — COVID-19 CPT Vaccine and Immunization Codes (2026)
- CMS — Annual Update to the List of CPT/HCPCS Codes Effective January 1, 2026
- ACDIS — CDI Query Standards
About this Guide
This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY2026 ICD-10-CM (effective October 1, 2025). All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.
Last reviewed: April 2026 · Next scheduled review: October 2026 (FY2027 update)
Ready to turn this knowledge into a credential?
These Clinical Documentation Guides are a free companion to CCO’s paid training programs. Browse our full CCO Course, Blitz & Practice Exam Catalog — every core course, review blitz, practice exam, textbook, and free resource in one place — and find the perfect next step for your coding career.
